Merck & Co., Inc. (NYSE:MRK – Get Free Report) EVP Richard Deluca sold 11,699 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Merck & Co., Inc. Trading Up 2.0%
NYSE MRK opened at $135.57 on Friday. The firm has a market capitalization of $334.49 billion, a price-to-earnings ratio of 108.46, a PEG ratio of 5.73 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.68. The company’s 50 day moving average price is $125.25 and its 200 day moving average price is $119.83.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the prior year, the business earned $2.13 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current year.
Merck & Co., Inc. Dividend Announcement
Wall Street Analysts Forecast Growth
A number of research analysts have commented on MRK shares. Argus boosted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. BMO Capital Markets raised their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Guggenheim upped their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Morgan Stanley upped their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $135.50.
Read Our Latest Analysis on MRK
More Merck & Co., Inc. News
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
- Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
- Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
- Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
- Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
- Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article
Institutional Trading of Merck & Co., Inc.
Large investors have recently modified their holdings of the business. Osbon Capital Management LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at about $279,000. LM Advisors LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $1,814,000. TrinityBridge Ltd purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $446,000. Jupiter Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $1,773,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $969,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.
About Merck & Co., Inc.
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
